Q4 2025 BioHarvest Sciences Inc Earnings Call Transcript
Key Points
- BioHarvest Sciences Inc (BHST) reported a 25% year-over-year increase in fourth-quarter revenues, reaching $9.1 million, driven by strong sales in their VINIA nutraceutical platform.
- The company achieved a gross margin of 58% for the fourth quarter, up 100 basis points from the previous year, indicating improved manufacturing efficiency and revenue mix.
- BioHarvest's VINIA BloodFlow Hydration product has shown promising early results, becoming the number two contributor to new customer sales and receiving high ratings on both vinia.com and Amazon.
- The CDMO business unit generated approximately $2 million in third-party revenue in 2025, with significant progress in multiple high-value projects, including a fragrance program and collaborations with companies like Tate & Lyle.
- BioHarvest has a strong cash position, with cash and cash equivalents totaling $23 million as of December 31, 2025, providing a solid foundation for future investments and growth initiatives.
- Despite revenue growth, BioHarvest Sciences Inc (BHST) reported a net loss of $2.2 million for the fourth quarter of 2025, although this was an improvement from the previous year's loss.
- Operating expenses increased to $6.3 million in the fourth quarter, primarily due to higher marketing spend and expenses from the CDMO service division.
- The ongoing conflict in the Middle East poses potential risks to BioHarvest's operations, although the company has managed to maintain continuous operations so far.
- The CDMO business, while showing potential, is still in the early stages of development and requires significant investment to reach its full potential.
- BioHarvest's shift in marketing strategy towards digital channels like TikTok and Instagram is still in the optimization phase, and it remains to be seen how effective these changes will be in acquiring younger customers.
Hello, everyone. Thank you for joining us, and welcome to the BioHarvest Sciences Fourth Quarter and Year-End 2025 Earnings Call. (Operator Instructions) I will now hand the call over to Justin Meiklem, Head of Investor Relations. Please go ahead.
Greetings. With us on the call are Dr. Zaki Rakib, Chairman; Ilan Sobel, Chief Executive Officer; and Bar Dichter, Chief Financial Officer.
Before we begin, I'd like to remind you that management will be making projections and forward-looking statements on the call today regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. We encourage you to review BioHarvest Sciences' SEC filings, including the company's most recent Form 40-F, which identify risks and uncertainties that may cause future actual results or events to differ materially. These filings can be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
